143 related articles for article (PubMed ID: 16565239)
1. Randomized clinical trials on surrogate end points: are they useful for evaluating cardiovascular and renal disease protection in hypertension? The case for yes.
Morganti A
J Am Soc Nephrol; 2006 Apr; 17(4 Suppl 2):S141-4. PubMed ID: 16565239
[TBL] [Abstract][Full Text] [Related]
2. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
Weir MR
Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
[TBL] [Abstract][Full Text] [Related]
3. [What do large clinical trials learn us about cardiovascular and renal prevention in patients with type 2 diabetes mellitus and hypertension?].
Dussol B; Berland Y
Nephrol Ther; 2006 May; 2(2):51-74. PubMed ID: 16895717
[TBL] [Abstract][Full Text] [Related]
4. Reduction in albuminuria translates to reduction in cardiovascular events in hypertensive patients with left ventricular hypertrophy and diabetes.
Ibsen H; Olsen MH; Wachtell K; Borch-Johnsen K; Lindholm LH; Mogensen CE
J Nephrol; 2008; 21(4):566-9. PubMed ID: 18651547
[TBL] [Abstract][Full Text] [Related]
5. The evaluation of the results of clinical trials: surrogate end points and composite end points.
Gensini GF; Conti AA
Minerva Med; 2004 Feb; 95(1):71-5. PubMed ID: 15041928
[TBL] [Abstract][Full Text] [Related]
6. Left ventricular hypertrophy versus chronic kidney disease as predictors of cardiovascular events in hypertension: a Greek 6-year-follow-up study.
Tsioufis C; Vezali E; Tsiachris D; Dimitriadis K; Taxiarchou E; Chatzis D; Thomopoulos C; Syrseloudis D; Stefanadi E; Mihas C; Katsi V; Papademetriou V; Stefanadis C
J Hypertens; 2009 Apr; 27(4):744-52. PubMed ID: 19516174
[TBL] [Abstract][Full Text] [Related]
7. Microalbuminuria: do we need a new threshold?
Zamora CR; Cubeddu LX
J Hum Hypertens; 2009 Feb; 23(2):146-9. PubMed ID: 18784737
[TBL] [Abstract][Full Text] [Related]
8. [Subclinical albuminuria, microalbuminuria and proteinuria--accepted cardiovascular risk markers?].
Schmieder RE; Schrader J; Zidek W; Tebbe U; Bramlage P; Paar WD; Böhm M
Dtsch Med Wochenschr; 2006 Nov; 131(47):2665-71. PubMed ID: 17109277
[No Abstract] [Full Text] [Related]
9. ["Soft" and "hard" end points in the example of hypertension].
Düsing R
Dtsch Med Wochenschr; 2006 May; 131(19 Suppl 1):S21-6. PubMed ID: 16688661
[TBL] [Abstract][Full Text] [Related]
10. The effect of baseline physical activity on cardiovascular outcomes and new-onset diabetes in patients treated for hypertension and left ventricular hypertrophy: the LIFE study.
Fossum E; Gleim GW; Kjeldsen SE; Kizer JR; Julius S; Devereux RB; Brady WE; Hille DA; Lyle PA; Dahlöf B
J Intern Med; 2007 Oct; 262(4):439-48. PubMed ID: 17875180
[TBL] [Abstract][Full Text] [Related]
11. Rationale, design and patient baseline characteristics of OlmeSartan and calcium antagonists randomized (OSCAR) study: a study comparing the incidence of cardiovascular events between high-dose angiotensin II receptor blocker (ARB) monotherapy and combination therapy of ARB with calcium channel blocker in Japanese elderly high-risk hypertensive patients (ClinicalTrials. gov no. NCT00134160).
Ogawa H; Kim-Mitsuyama S; Jinnouchi T; Matsui K; Arakawa K
Hypertens Res; 2009 Jul; 32(7):575-80. PubMed ID: 19444280
[TBL] [Abstract][Full Text] [Related]
12. Macroalbuminuria and microalbuminuria: do both predict renal and cardiovascular events with similar strength?
de Jong PE; Gansevoort RT; Bakker SJ
J Nephrol; 2007; 20(4):375-80. PubMed ID: 17879201
[TBL] [Abstract][Full Text] [Related]
13. ESH-ESC guidelines for the management of hypertension.
Erdine S; Ari O; Zanchetti A; Cifkova R; Fagard R; Kjeldsen S; Mancia G; Poulter N; Rahn KH; Rodicio JL; Ruilope LM; Staessen J; van Zwieten P; Waeber B; Williams B
Herz; 2006 Jun; 31(4):331-8. PubMed ID: 16810473
[TBL] [Abstract][Full Text] [Related]
14. Relationship between the achieved blood pressure and the incidence of cardiovascular events in Japanese hypertensive patients with complications: a sub-analysis of the CASE-J trial.
Ogihara T; Saruta T; Rakugi H; Fujimoto A; Ueshima K; Yasuno S; Oba K; Takeda K; Higaki J; Nakao K;
Hypertens Res; 2009 Apr; 32(4):248-54. PubMed ID: 19347033
[TBL] [Abstract][Full Text] [Related]
15. Complications of hypertension and the role of angiotensin receptor blockers in hypertension trials.
Flaa A; Aksnes TA; Strand A; Kjeldsen SE
Expert Rev Cardiovasc Ther; 2007 May; 5(3):451-61. PubMed ID: 17489670
[TBL] [Abstract][Full Text] [Related]
16. Potential mechanisms of stroke benefit favoring losartan in the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study.
Devereux RB; Dahlöf B
Curr Med Res Opin; 2007 Feb; 23(2):443-57. PubMed ID: 17288698
[TBL] [Abstract][Full Text] [Related]
17. Prediction of cardiovascular outcome by estimated glomerular filtration rate and estimated creatinine clearance in the high-risk hypertension population of the VALUE trial.
Ruilope LM; Zanchetti A; Julius S; McInnes GT; Segura J; Stolt P; Hua TA; Weber MA; Jamerson K;
J Hypertens; 2007 Jul; 25(7):1473-9. PubMed ID: 17563571
[TBL] [Abstract][Full Text] [Related]
18. Prognostic importance of hemoglobin in hypertensive patients with electrocardiographic left ventricular hypertrophy: the Losartan Intervention For End point reduction in hypertension (LIFE) study.
Olsen MH; Wachtell K; Beevers G; Dahlöf B; Devereux RB; de Faire U; Fyhrquist F; Ibsen H; Kjeldsen SE; Lederballe-Pedersen O; Lindholm LH; Narayan P; Nieminen MS; Omvik P; Oparil S; Wedel H
Am Heart J; 2009 Jan; 157(1):177-84. PubMed ID: 19081416
[TBL] [Abstract][Full Text] [Related]
19. Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE): rationale and study design.
Parving HH; Brenner BM; McMurray JJ; de Zeeuw D; Haffner SM; Solomon SD; Chaturvedi N; Ghadanfar M; Weissbach N; Xiang Z; Armbrecht J; Pfeffer MA
Nephrol Dial Transplant; 2009 May; 24(5):1663-71. PubMed ID: 19145003
[TBL] [Abstract][Full Text] [Related]
20. When hypertension and diabetes coexist: strategies for cardiorenal protection.
Weber MA
Postgrad Med; 2000 Oct; 108(5 Suppl):12-8. PubMed ID: 19667536
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
